AGP Picks
View all

Essential Healthcare News
Provided by AGP

Essential Healthcare News: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Essential Healthcare News.

June 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30

July 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30 31

August 2026

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30
31

Press releases published on June 18, 2026

Asimov Announces Strategic Partnership with the Rosalind & Morris Goodman Cancer Institute at McGill University to Advance Next-Generation Biologics
Jun. 18, 2026

Asimov Announces Strategic Partnership with the Rosalind & Morris Goodman Cancer Institute at McGill University to Advance Next-Generation Biologics

Indeterminate GlobeNewswire
CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Jun. 18, 2026

CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042

Indeterminate GlobeNewswire
Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies
Jun. 18, 2026

Alturos Therapeutics advancement of lead candidate ALT0135, a potentially first-in-class, orally bioavailable small molecule, into IND-enabling studies

Indeterminate GlobeNewswire
Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement
Jun. 18, 2026

Alvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private Placement

Indeterminate GlobeNewswire
New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF
Jun. 18, 2026

New analyses from FIBRONEER™ trials suggest survival benefit with nerandomilast in IPF and PPF

Indeterminate GlobeNewswire
Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares
Jun. 18, 2026

Alvotech Announces Proposed $125 Million Public Offering and Concurrent Private Placement of Ordinary Shares

Indeterminate GlobeNewswire
BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum
Jun. 18, 2026

BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum

Indeterminate GlobeNewswire
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Jun. 18, 2026

Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470

Indeterminate GlobeNewswire
Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470
Jun. 18, 2026

Nicox annonce des retours réglementaires préalables positifs en Chine soutenant le dépôt du NDA pour NCX 470

Indeterminate GlobeNewswire
F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis
Jun. 18, 2026

F2G and Shionogi Announce Positive Topline Results From Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients With Invasive Aspergillosis

Indeterminate GlobeNewswire
Legend Biotech Corporation Announces Pricing of Public Offering
Jun. 18, 2026

Legend Biotech Corporation Announces Pricing of Public Offering

Indeterminate GlobeNewswire

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Essential Healthcare News

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.